Nothing Special   »   [go: up one dir, main page]

MA49956B1 - Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak - Google Patents

Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak

Info

Publication number
MA49956B1
MA49956B1 MA49956A MA49956A MA49956B1 MA 49956 B1 MA49956 B1 MA 49956B1 MA 49956 A MA49956 A MA 49956A MA 49956 A MA49956 A MA 49956A MA 49956 B1 MA49956 B1 MA 49956B1
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
compounds used
pyrimidine compounds
jak kinase
compounds
Prior art date
Application number
MA49956A
Other languages
English (en)
Other versions
MA49956A (fr
Inventor
Marta Dabros
Robert Murray Mckinnell
Jerry Nzerem
Jennifer Kozak
Ryan Hudson
Gary E L Brandt
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MA49956A publication Critical patent/MA49956A/fr
Publication of MA49956B1 publication Critical patent/MA49956B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)

Abstract

L'invention concerne un composé de formule (i) : (formule (i)) ou un sel pharmaceutiquement acceptable de celui-ci, qui est utile en tant qu'inhibiteur de kinases jak. La présente invention concerne également des compositions pharmaceutiques comprenant de tels composés, une forme cristalline, des procédés d'utilisation de ces composés pour traiter des maladies cutanées inflammatoires et d'autres maladies, et des procédés et intermédiaires utiles dans la préparation de tels composés.
MA49956A 2017-10-27 2018-10-26 Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak MA49956B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
PCT/US2018/057682 WO2019084383A1 (fr) 2017-10-27 2018-10-26 Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak

Publications (2)

Publication Number Publication Date
MA49956A MA49956A (fr) 2020-07-01
MA49956B1 true MA49956B1 (fr) 2022-11-30

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49956A MA49956B1 (fr) 2017-10-27 2018-10-26 Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak

Country Status (37)

Country Link
US (7) US10308646B2 (fr)
EP (1) EP3672965B1 (fr)
JP (1) JP7218364B2 (fr)
KR (1) KR102613503B1 (fr)
CN (1) CN111247142B (fr)
AR (1) AR113803A1 (fr)
AU (1) AU2018354370B2 (fr)
BR (1) BR112020008015A2 (fr)
CA (1) CA3074034A1 (fr)
CL (1) CL2020001090A1 (fr)
CR (1) CR20200180A (fr)
CU (1) CU24671B1 (fr)
DK (1) DK3672965T3 (fr)
DO (1) DOP2020000083A (fr)
EA (1) EA202091016A1 (fr)
EC (1) ECSP20023795A (fr)
ES (1) ES2932526T3 (fr)
GE (1) GEP20227344B (fr)
HR (1) HRP20221221T1 (fr)
HU (1) HUE060401T2 (fr)
IL (1) IL274037B2 (fr)
LT (1) LT3672965T (fr)
MA (1) MA49956B1 (fr)
MD (1) MD3672965T2 (fr)
MX (1) MX2020004255A (fr)
NI (1) NI202000032A (fr)
PE (1) PE20201495A1 (fr)
PH (1) PH12020500528A1 (fr)
PL (1) PL3672965T3 (fr)
PT (1) PT3672965T (fr)
RS (1) RS63608B1 (fr)
SG (1) SG11202001706RA (fr)
SI (1) SI3672965T1 (fr)
TW (1) TWI789446B (fr)
UA (1) UA125130C2 (fr)
WO (1) WO2019084383A1 (fr)
ZA (1) ZA202001641B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200180A (es) 2017-10-27 2020-08-12 Theravance Biopharma R&D Ip Llc Compuesto de pirimidina como inhibidor de las janocinasas
WO2020108613A1 (fr) * 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 Dérivés hétéroaromatiques destinés à être utilisés comme régulateurs, leur procédé de préparation et leur utilisation
CA3135388A1 (fr) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Inhibiteurs de jak a base de pyrimidine pour le traitement de maladies de la peau
HRP20240346T1 (hr) 2019-04-24 2024-05-24 Theravance Biopharma R&D Ip, Llc Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze
JP7572538B2 (ja) 2020-07-28 2024-10-23 アーキュティス・バイオセラピューティクス・インコーポレーテッド Ｊａｋ阻害剤およびラウレス－４を含有する局所配合物
AU2021333760A1 (en) * 2020-08-26 2023-04-06 Nalo Therapeutics Modulators of Myc family proto-oncogene protein
EP4225438A1 (fr) * 2020-10-08 2023-08-16 Icahn School of Medicine at Mount Sinai Compositions pour le traitement de l'alopécie aréata, biomarqueurs pour le succès du traitement, et leurs méthodes d'utilisation
CA3236262A1 (fr) 2021-10-25 2023-05-04 Isaac Marx Agents de degradation de tyk2 et leurs utilisations
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4105947B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なトリアゾール化合物
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2588220A1 (fr) * 2004-12-23 2006-06-29 Pfizer Products Inc. Derives heteroaromatiques utiles en tant qu'agents anticancereux
JP2009515992A (ja) 2005-11-16 2009-04-16 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なアミノピリミジン
EP2044063A1 (fr) 2006-06-30 2009-04-08 Astra Zeneca AB Dérivés de pyrimidine utiles dans le traitement du cancer
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
CN104011050A (zh) 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
WO2015094803A1 (fr) 2013-12-16 2015-06-25 Calitor Sciences, Llc Composés hétéroaryles substitués et méthodes d'utilisation
NO2721710T3 (fr) * 2014-08-21 2018-03-31
CN106687467A (zh) 2014-09-30 2017-05-17 韩美精密化学株式会社 高纯度（r）‑9‑[2‑（磷酰甲氧基）丙基]腺嘌呤的制备方法
ES2753159T3 (es) * 2015-05-28 2020-04-07 Theravance Biopharma R&D Ip Llc Compuestos de naftiridina como inhibidores de quinasa JAK
JP2018527362A (ja) * 2015-09-11 2018-09-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換されたヘテロアリール化合物および使用方法
AU2017258186B2 (en) * 2016-04-28 2020-09-17 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as JAK kinase inhibitors
CR20200180A (es) * 2017-10-27 2020-08-12 Theravance Biopharma R&D Ip Llc Compuesto de pirimidina como inhibidor de las janocinasas
CA3135388A1 (fr) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Inhibiteurs de jak a base de pyrimidine pour le traitement de maladies de la peau
HRP20240346T1 (hr) 2019-04-24 2024-05-24 Theravance Biopharma R&D Ip, Llc Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze

Also Published As

Publication number Publication date
US20220396573A1 (en) 2022-12-15
US20200369660A1 (en) 2020-11-26
ES2932526T3 (es) 2023-01-20
US20240158389A1 (en) 2024-05-16
US20210214349A1 (en) 2021-07-15
IL274037A (en) 2020-06-30
AR113803A1 (es) 2020-06-10
PE20201495A1 (es) 2020-12-29
US10308646B2 (en) 2019-06-04
US20190127364A1 (en) 2019-05-02
HUE060401T2 (hu) 2023-02-28
IL274037B1 (en) 2023-07-01
AU2018354370A1 (en) 2020-04-09
AU2018354370B2 (en) 2023-04-27
US11420965B2 (en) 2022-08-23
RS63608B1 (sr) 2022-10-31
NI202000032A (es) 2020-10-09
JP2021501151A (ja) 2021-01-14
MA49956A (fr) 2020-07-01
ZA202001641B (en) 2021-04-28
DK3672965T3 (da) 2022-10-03
US10562894B2 (en) 2020-02-18
PH12020500528A1 (en) 2021-06-07
CR20200180A (es) 2020-08-12
HRP20221221T1 (hr) 2022-12-09
MX2020004255A (es) 2020-07-29
LT3672965T (lt) 2022-10-10
CA3074034A1 (fr) 2019-05-02
US20190241555A1 (en) 2019-08-08
BR112020008015A2 (pt) 2020-10-27
US11814377B2 (en) 2023-11-14
US10988470B2 (en) 2021-04-27
EA202091016A1 (ru) 2020-07-17
CN111247142B (zh) 2022-12-02
IL274037B2 (en) 2023-11-01
SG11202001706RA (en) 2020-03-30
ECSP20023795A (es) 2020-06-30
CN111247142A (zh) 2020-06-05
KR102613503B1 (ko) 2023-12-13
SI3672965T1 (sl) 2022-11-30
TWI789446B (zh) 2023-01-11
EP3672965A1 (fr) 2020-07-01
UA125130C2 (uk) 2022-01-12
PT3672965T (pt) 2022-09-29
KR20200078517A (ko) 2020-07-01
GEP20227344B (en) 2022-01-25
DOP2020000083A (es) 2020-08-15
PL3672965T3 (pl) 2023-01-16
MD3672965T2 (ro) 2022-12-31
WO2019084383A1 (fr) 2019-05-02
US10774080B2 (en) 2020-09-15
CL2020001090A1 (es) 2020-08-21
EP3672965B1 (fr) 2022-09-07
CU20200053A7 (es) 2021-03-11
CU24671B1 (es) 2023-07-12
JP7218364B2 (ja) 2023-02-06
US20200140430A1 (en) 2020-05-07
TW201930304A (zh) 2019-08-01

Similar Documents

Publication Publication Date Title
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu&#39;inhibiteurs de kinase jak
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MA47970B1 (fr) Composé inhibiteur de jak à base d&#39;imidazo-pipéridine fusionnée
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu&#39;inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu&#39;inhibiteurs de prmt5
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA41179A (fr) Composés inhibiteurs de parg
EP4374858A3 (fr) Dérivés de la benzimidazolone en tant qu&#39;inhibiteurs du récepteur bcl6
MA38380A1 (fr) Inhibiteurs quinazoline de l&#39;activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
TW200618804A (en) Phosphonate analogs of HIV inhibitor compounds
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA46229B1 (fr) Composés d&#39;hétéroaryle carboxamide en tant qu&#39;inhibiteurs de ripk2
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA49127B1 (fr) Dérivés d&#39;indole n-substitués
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
WO2020247298A3 (fr) Dérivés d&#39;indazole 5 -, 6-disubstitués, 1-pyrazolyle, en tant qu&#39;inhibiteurs de lrrk2, compositions pharmaceutiques et utilisations correspondantes
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
WO2023073013A8 (fr) Inhibiteurs de lrrk2
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique